Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?

INTRODUCTION: The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) announced conditions for using recombinant human interleukin-1 receptor antagonist (rhIL-1ra) to treat hospitalized patients with Coronavirus disease 2019 (COVID-19) and risk for progression. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Leland, Scherger, Sias, Franco-Paredes, Carlos, Gharamti, Amal, Henao-Martinez, Andrés F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620707/
https://www.ncbi.nlm.nih.gov/pubmed/37928695
http://dx.doi.org/10.3389/fmicb.2023.1250483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620707/
https://www.ncbi.nlm.nih.gov/pubmed/37928695
http://dx.doi.org/10.3389/fmicb.2023.1250483

Ejemplares similares